Improving family experiences of newly diagnosed childhood cancer
News Stories
A Luminesce Alliance-supported study PREDICT published by the British Journal of Cancer March 2026 explores parents’ and patients’ experiences of trio germline whole genome sequencing for newly diagnosed childhood cancer. The study was a pilot for the germline component of the ZERO2 trial.
The study, entitled “I Don’t Think I Even Thought of Myself” A Mixed-Methods Study of Family Experiences of Trio Germline Whole Genome Sequencing in Newly Diagnosed Childhood Cancer, found that consent for trio-GGS at cancer diagnosis is complex, requiring flexible, tailored processes. Clear, timely communication from trusted clinicians is key to improving family experiences.
Authors: Hunter, J.D., Hetherington, K. (pictured L-R), McGillycuddy, M., Wakefield, C.E., Tucker, K.M., O,Brien, T.A., McGill, B.C., Fuentes-Bolanos, N.A., Bhatia, K., Padhye, B., Grant, A., Barlow-Stewart, K., Warby, M., Courtney, E., Peate, M.